vimarsana.com
Home
Live Updates
Preclinical Data Demonstrate Anti-Siglec-15 Treatment Reduce
Preclinical Data Demonstrate Anti-Siglec-15 Treatment Reduce
Preclinical Data Demonstrate Anti-Siglec-15 Treatment Reduced Bone Loss and Enhanced Bone Quality in Mice with Moderate-to-Severe Osteogenesis Imperfecta (OI)
Data Presented at the 2023 American Society for Bone and Mineral Research Annual MeetingBELTSVILLE, Md., Oct. 17, 2023 -- NextCure, Inc. , a clinical-stage biopharmaceutical company committed to...
Related Keywords
United States ,
Hospital For Special Surgery ,
New York ,
American ,
Timothy Mayer ,
Cathleen Raggio ,
Exchange Commission ,
Mineral Research ,
Nasdaq ,
Pamerican Society For Bone ,
Nextcure Inc ,
Data Presented ,
Transform Infrared ,
Solomon Langermann ,
Special Surgery ,
Sexual Dimorphism ,
Treatment Effect ,
Adult Mice ,
Moderate To Severe Osteogenesis ,
Markets ,